Biomarker-Based Targeting of the Androgen-Androgen Receptor Axis in Advanced Prostate Cancer
Recent therapeutic advances for managing advanced prostate cancer include the successful targeting of the androgen-AR axis with several new drugs in castrate resistant prostate cancer including abiraterone acetate and enzalutamide (MDV3100). This translational progress from “bench to bed-side” has r...
Saved in:
| Main Authors: | , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Wiley
2012-01-01
|
| Series: | Advances in Urology |
| Online Access: | http://dx.doi.org/10.1155/2012/781459 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| _version_ | 1832552641576566784 |
|---|---|
| author | Manish Kohli Rui Qin Rafael Jimenez Scott M. Dehm |
| author_facet | Manish Kohli Rui Qin Rafael Jimenez Scott M. Dehm |
| author_sort | Manish Kohli |
| collection | DOAJ |
| description | Recent therapeutic advances for managing advanced prostate cancer include the successful targeting of the androgen-AR axis with several new drugs in castrate resistant prostate cancer including abiraterone acetate and enzalutamide (MDV3100). This translational progress from “bench to bed-side” has resulted in an enlarging repertoire of novel and traditional drug choices now available for use in advanced prostate cancer therapeutics, which has had a positive clinical impact in prolonging longevity and quality of life of advanced prostate cancer patients. In order to further the clinical utility of these drugs, development of predictive biomarkers guiding individual therapeutic choices remains an ongoing challenge. This paper will summarize the potential in developing predictive biomarkers based on the pathophysiology of the androgen-AR axis in tumor tissue from patients with advanced prostate cancer as well as inherited variation in the patient’s genome. Specific examples of rational clinical trial designs incorporating potential predictive biomarkers from these pathways will illustrate several aspects of pharmacogenetic and pharmacogenomic predictive biomarker development in advanced prostate cancer therapeutics. |
| format | Article |
| id | doaj-art-587466b7b9114d92848d567438add535 |
| institution | Kabale University |
| issn | 1687-6369 1687-6377 |
| language | English |
| publishDate | 2012-01-01 |
| publisher | Wiley |
| record_format | Article |
| series | Advances in Urology |
| spelling | doaj-art-587466b7b9114d92848d567438add5352025-02-03T05:58:13ZengWileyAdvances in Urology1687-63691687-63772012-01-01201210.1155/2012/781459781459Biomarker-Based Targeting of the Androgen-Androgen Receptor Axis in Advanced Prostate CancerManish Kohli0Rui Qin1Rafael Jimenez2Scott M. Dehm3Department of Oncology, Mayo Clinic, 200 First Street SW, Rochester, MN 55905, USADepartment of Health Sciences Research, Mayo Clinic, 200 First Street SW, Rochester, MN 55905, USADepartment of Laboratory Medicine and Pathology, Mayo Clinic, 200 First Street SW, Rochester, MN 55905, USAMasonic Cancer Center and Department of Laboratory Medicine and Pathology, University of Minnesota, Minneapolis, MN 55455, USARecent therapeutic advances for managing advanced prostate cancer include the successful targeting of the androgen-AR axis with several new drugs in castrate resistant prostate cancer including abiraterone acetate and enzalutamide (MDV3100). This translational progress from “bench to bed-side” has resulted in an enlarging repertoire of novel and traditional drug choices now available for use in advanced prostate cancer therapeutics, which has had a positive clinical impact in prolonging longevity and quality of life of advanced prostate cancer patients. In order to further the clinical utility of these drugs, development of predictive biomarkers guiding individual therapeutic choices remains an ongoing challenge. This paper will summarize the potential in developing predictive biomarkers based on the pathophysiology of the androgen-AR axis in tumor tissue from patients with advanced prostate cancer as well as inherited variation in the patient’s genome. Specific examples of rational clinical trial designs incorporating potential predictive biomarkers from these pathways will illustrate several aspects of pharmacogenetic and pharmacogenomic predictive biomarker development in advanced prostate cancer therapeutics.http://dx.doi.org/10.1155/2012/781459 |
| spellingShingle | Manish Kohli Rui Qin Rafael Jimenez Scott M. Dehm Biomarker-Based Targeting of the Androgen-Androgen Receptor Axis in Advanced Prostate Cancer Advances in Urology |
| title | Biomarker-Based Targeting of the Androgen-Androgen Receptor Axis in Advanced Prostate Cancer |
| title_full | Biomarker-Based Targeting of the Androgen-Androgen Receptor Axis in Advanced Prostate Cancer |
| title_fullStr | Biomarker-Based Targeting of the Androgen-Androgen Receptor Axis in Advanced Prostate Cancer |
| title_full_unstemmed | Biomarker-Based Targeting of the Androgen-Androgen Receptor Axis in Advanced Prostate Cancer |
| title_short | Biomarker-Based Targeting of the Androgen-Androgen Receptor Axis in Advanced Prostate Cancer |
| title_sort | biomarker based targeting of the androgen androgen receptor axis in advanced prostate cancer |
| url | http://dx.doi.org/10.1155/2012/781459 |
| work_keys_str_mv | AT manishkohli biomarkerbasedtargetingoftheandrogenandrogenreceptoraxisinadvancedprostatecancer AT ruiqin biomarkerbasedtargetingoftheandrogenandrogenreceptoraxisinadvancedprostatecancer AT rafaeljimenez biomarkerbasedtargetingoftheandrogenandrogenreceptoraxisinadvancedprostatecancer AT scottmdehm biomarkerbasedtargetingoftheandrogenandrogenreceptoraxisinadvancedprostatecancer |